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Abstract 
The diagnosis of multiple sclerosis, after exclusion of its mimics, is based on the objective 
evidence of central nervous system involvement and dissemination of demyelinating lesions 
in time and space. The correct application of the current diagnostic criteria enables early 
diagnosis of MS and prompt commencement of disease-modifying therapies. We provide a 
diagram that summarises the McDonald 2017 diagnostic criteria, which may serve both MS 
experts and general neurologists in the diagnostic process of multiple sclerosis. We also 
briefly comment on the advantages of using the new diagnostic criteria and stress the 




The diagnostic criteria for multiple sclerosis (MS), first developed in the 1950s, have since 
undergone several revisions, all focused on three main requirements for a diagnosis of MS: 
1) objective clinical evidence of central nervous system (CNS) involvement; 2) evidence of 
lesions disseminated in time (DIT) and space (DIS); 3) exclusion of other conditions that 
could better explain the clinical and paraclinical findings. Before the widespread use of 
magnetic resonance imaging (MRI), DIT and DIS were fulfilled by two attacks involving 
different parts of the CNS and clinical evidence of two lesions separated in time, or one 
attack with additional paraclinical evidence of another lesion. In 2001, McDonald et al. fully 
integrated the use of MRI into the diagnostic schema as an alternative to clinical evidence 
for DIS and DIT, allowing an earlier diagnosis of MS.[1] Based on new evidence for the role 
of MRI, the McDonald criteria were revised in 2005, 2010, and 2017.[2–4] Given the 
increasing focus on the importance of early treatment of MS with disease-modifying 
therapies, a prompt and accurate diagnosis of MS has never been more important.  
 
Previous diagnostic criteria 
The 2010 revisions to the McDonald criteria simplified the requirements for DIS and DIT on 
MRI and removed neurophysiological and cerebrospinal fluid (CSF) testing from the 
diagnostic criteria (for relapsing-remitting MS). DIS on MRI required at least one T2 lesion in 
at least two of four locations characteristic of MS (periventricular, juxtacortical, 
infratentorial and spinal cord), and DIT required the simultaneous presence of gadolinium-
enhancing and non-enhancing lesions, or a new T2 or gadolinium-enhancing lesion on a 
follow-up MRI. For the first time, a diagnosis of MS could be made in some clinically isolated 
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syndrome (CIS) patients with a single contrast-enhanced MRI scan. However, there were 
two main caveats: 1) the criteria would only be applied when MS was already the most likely 
diagnosis, and where this was not the case, then both neurophysiological and CSF studies 
still had a clear role; 2) the criteria treated symptomatic and asymptomatic lesions 
differently: only asymptomatic lesions could contribute to DIS and DIT using MRI.  
 
The main changes in the new diagnostic criteria 
The 2017 revision of the McDonald criteria (Figure 1) further simplify the diagnostic process 
in patients with CIS.  The first major change is the reintroduction of CSF oligoclonal bands, 
which have been shown to predict a second clinical attack following a CIS in patients with 
MRI evidence of DIS. [5] In a typical CIS patient with DIS, the presence of unmatched CSF 
oligoclonal bands now permits a diagnosis of MS, even without DIT on MRI or a second 
attack (Figure 2). Moreover, there is no longer a distinction between symptomatic or 
asymptomatic lesions, and both, with the exception of optic nerve lesions, can contribute to 
the MRI determination of DIS or DIT. The 2017 Criteria also allow for cortical lesions, which 
are common in MS, to contribute to the determination of MRI DIS. The requirements for the 
diagnosis of primary progressive MS have not changed compared to past versions, apart 
from the removal of the distinction between symptomatic and asymptomatic lesions and 
the inclusion of cortical lesions. 
 
Commentary 
MRI can demonstrate DIT and DIS, which are at the core of MS diagnosis, and the revised 
criteria now recognise cortical involvement in MS while also simplifying the MRI DIS and DIT 
requirements. However, MRI lesions similar to that found in MS can be seen in other 
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disorders, and MRI criteria should not be applied in patients with atypical clinical 
presentations.[6] If there is doubt regarding the nature of symptoms or signs, further 
evaluation should be carried out.[7] The 2017 criteria should be applied with caution in 
geographical areas with a lower incidence of MS, in younger children and older adults, and 
those with comorbidities (e.g. migraine or small vessel disease) in order to avoid 
misdiagnosis. Particular attention is necessary to rule out neuromyelitis optica spectrum 
disorder, especially in African-American, Asian, Latin American, and paediatric populations, 
where this disease is relatively more common. There remains further scope for the current 
2017 diagnostic criteria to be further refined, for example, despite the specificity of cortical 
lesions for MS they still cannot be detected as easily as white matter lesions using MRI 
techniques available clinically. The visual system is also often involved in MS, yet the role of 
optic nerve MRI, visual evoked potentials, or optical coherence tomography in fulfilling DIS 
or DIT remains uncertain. Moreover, the incidental finding of MRI white matter lesions that 
fulfil MS radiological diagnostic criteria (termed a radiologically isolated syndrome [RIS]), 
remains a cause of clinical uncertainly that the 2017 criteria have not resolved [8].  
Changes in MS diagnostic criteria have also raised questions about the use of DMTs 
following a CIS. The evidence for DMT use following a CIS comes from clinical trials that used 
pre-2010 diagnostic criteria, i.e. where a significant proportion of those enrolled in studies 
would now fulfil diagnostic criteria for MS, and so it is unclear if their efficacy would be the 
same in people now classified as having a CIS rather than MS. This point has recently been a 
matter of discussion for the National Institute for Health and Care Excellence.” [9]  
In conclusion, the new diagnostic criteria can be applied easily and allow for a more stream-
lined diagnosis of MS. However, they do not replace physicianly judgement and should 
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 Figure 1. Diagram or visual summary of the last revision of the MS Diagnostic Criteria 
 
According to the glossary provided by Thompson et al. [4], in the figure, the term “lesion(s)” refers to “an 
area of hyperintensity on a T2-weighted or proton-density weighted MRI scan that is at least 3 mm in long 
axis.” 
 
CIS= clinically isolated syndrome. CNS= central nervous system. CSF= cerebrospinal fluid. DIS= 
dissemination in space. DIT= dissemination in time. MRI= magnetic resonance imaging. MS= multiple 
sclerosis. WM= white matter. 
 Figure 2. Case Scenario 
Adapted clinical case showing different diagnostic outcomes after the application of the old and the new 
diagnostic criteria.  
*The presence of CSF-specific oligoclonal bands does not conclusively demonstrate dissemination in time 
per se but can substitute for the requirement for demonstration of this measure. 
CE= contrast enhancement. CSF= cerebrospinal fluid. Gad: gadolinium. MRI= magnetic resonance imaging. 
OCBs= oligoclonal bands.  
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